NCT05829889 Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease
| NCT ID | NCT05829889 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seung-Jung Park |
| Condition | Coronary Artery Disease Left Main |
| Study Type | INTERVENTIONAL |
| Enrollment | 960 participants |
| Start Date | 2024-04-25 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 960 participants in total. It began in 2024-04-25 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary purpose of the study was to determine whether the 2-year probability of major adverse cardiac events (primary composite outcome) differed significantly between patients who underwent angiography-guided Percutaneous Coronary Intervention(PCI) and those who underwent Fractional Flow Reserve(FFR)-guided PCI in patients with Left Main Coronary Artery disease(LMCA).
Eligibility Criteria
Inclusion Criteria: 1. The subject must be ≥20 years of age with angina and/or evidence of myocardial ischemia. 2. Significant de novo LMCA disease, defined as ≥ 50% diameter stenosis by visual estimation with or without concomitant non-left main major epicardial coronary artery disease, amenable to PCI with drug-eluting stent(DES) implantation. 3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site. Exclusion Criteria: 1. left anterior descending coronary artery (LAD) or left circumflex coronary artery (LCx) chronic total occlusion (CTO) 2. Extremely calcified or tortuous vessels precluding FFR measurement. 3. The presence of complex coronary disease anatomy or lesion characteristics or other cardiac condition(s) which leads the participating interventional cardiologist to believe that PCI is not suitable (i.e. the subject should be managed with coronary artery bypass graft or medical therapy alone). 4. Recent ST Elevation Myocardial Infarction(\<7 days prior to randomization). 5. Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support. 6. Severe left ventricular dysfunction (ejection fraction \<30%). 7. Requirement for other cardiac surgical procedure (e.g., valve replacement or aorta surgery). 8. Contraindication or inability to take aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, or clopidogrel). 9. Prior PCI of the left main trunk. 10. Prior coronary artery bypass graft surgery. 11. Subjects requiring or who may require additional surgery (cardiac or noncardiac) within 1 year. 12. End-stage renal disease requiring renal replacement therapy. 13. Liver cirrhosis. 14. Pregnant and/or lactating women. 15. Concurrent medical condition with a limited life expectancy of less than 2 years. 16. Subjects who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion; 1\) Participated in the observational study expected no effect on the safety and/or effectiveness evaluation of this trial. 2\) Screening failed before any interventional factor is involved. 3\) Participated in academic trials like strategic comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies.
Contact & Investigator
Duk-woo Park, MD
✉ dwpark@amc.seoul.krDuk-woo Park, MD
PRINCIPAL INVESTIGATOR
Asan Medical Center
Frequently Asked Questions
Who can join the NCT05829889 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Coronary Artery Disease Left Main. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05829889 currently recruiting?
Yes, NCT05829889 is actively recruiting participants. Contact the research team at dwpark@amc.seoul.kr for enrollment information.
Where is the NCT05829889 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong, Hong Kong, Hong Kong, Bangalore, India, Tokyo, Japan and 11 additional locations.
Who is sponsoring the NCT05829889 clinical trial?
NCT05829889 is sponsored by Seung-Jung Park. The principal investigator is Duk-woo Park, MD at Asan Medical Center. The trial plans to enroll 960 participants.